StreetInsider.com News Articles

Form SCHEDULE 13D/A GALECTIN THERAPEUTICS Filed by: Uihlein Richard E

Tue, 04 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260804/26862379.html

Form SCHEDULE 13D/A GALECTIN THERAPEUTICS Filed by: Uihlein Richard E

Tue, 04 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260804/26862379.html

Galectin Therapeutics converts $105.8M in debt to equity

Tue, 04 Aug 2026 08:04:36 -0400

Galectin Therapeutics Inc. (NASDAQ: GALT) announced that its chairman and largest stockholder, Richard E. Uihlein, converted approximately $105.8 million in outstanding debt into common stock, effective July 31, 2026.

The transaction eliminated $91.0 million in principal and approximately $14.8 million in accrued interest across five line of credit facilities. In exchange, the company issued 34,376,167 shares of common stock to Mr. Uihlein at a blended average conversion price of approximately $3.07 per share, based on pre-existing conversion rights under the applicable promissory notes.

Following the conversion, Galectin had 100,849,644 shares of common stock outstanding as of July 31, 2026.

The conversion covered notes

Galectin Therapeutics converts $105.8M in debt to equity

Tue, 04 Aug 2026 08:04:36 -0400

Following the conversion, Galectin had 100,849,644 shares of common stock outstanding as of July 31, 2026.

The conversion covered notes

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Tue, 04 Aug 2026 08:00:00 -0400

Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock

Transaction eliminates approximately $105.8 million in debt and increases market capitalization

NORCROSS, Ga., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT) ("Galectin" or the "Company"), a clinical-stage biopharmaceutical company developing therapies that target galectin-3 for the treatment of liver fibrosis and portal hypertension associated with MASH cirrhosis, today announced that Richard E. Uihlein, the Company’s Chairman of the Board and largest stockholder, has converted all outstanding principal and accrued interest under five of the Company’s

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Tue, 04 Aug 2026 08:00:00 -0400

Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock

Transaction eliminates approximately $105.8 million in debt and increases market capitalization

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Tue, 04 Aug 2026 08:00:00 -0400

Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock

Transaction eliminates approximately $105.8 million in debt and increases market capitalization

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Tue, 04 Aug 2026 08:00:00 -0400

Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock

Transaction eliminates approximately $105.8 million in debt and increases market capitalization

Form 4 GALECTIN THERAPEUTICS For: Jul 31 Filed by: Uihlein Richard E

Tue, 04 Aug 2026 07:52:00 -0400

si-local-file:///var/storage/secattach/20260804/26861738.html

Form 4 GALECTIN THERAPEUTICS For: Jul 31 Filed by: Uihlein Richard E

Tue, 04 Aug 2026 07:52:00 -0400

si-local-file:///var/storage/secattach/20260804/26861738.html

Form 8-K GALECTIN THERAPEUTICS For: Jul 31

Tue, 04 Aug 2026 07:50:00 -0400

si-local-file:///var/storage/secattach/20260804/26861729.html

Form 8-K GALECTIN THERAPEUTICS For: Jul 31

Tue, 04 Aug 2026 07:50:00 -0400

si-local-file:///var/storage/secattach/20260804/26861729.html

Form 4 GALECTIN THERAPEUTICS For: Jul 14 Filed by: Jamil Khurram

Thu, 16 Jul 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260716/26780744.html

Form 4 GALECTIN THERAPEUTICS For: Jul 14 Filed by: Jamil Khurram

Thu, 16 Jul 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260716/26780744.html

Form 4 GALECTIN THERAPEUTICS For: Jun 26 Filed by: Shlevin Harold H.

Tue, 30 Jun 2026 19:24:00 -0400

si-local-file:///var/storage/secattach/20260630/26715187.html

Form 4 GALECTIN THERAPEUTICS For: Jun 26 Filed by: Shlevin Harold H.

Tue, 30 Jun 2026 19:24:00 -0400

si-local-file:///var/storage/secattach/20260630/26715187.html

Form 4 GALECTIN THERAPEUTICS For: Jun 26 Filed by: Jamil Khurram

Tue, 30 Jun 2026 19:23:00 -0400

si-local-file:///var/storage/secattach/20260630/26715185.html

Form 4 GALECTIN THERAPEUTICS For: Jun 26 Filed by: Jamil Khurram

Tue, 30 Jun 2026 19:23:00 -0400

si-local-file:///var/storage/secattach/20260630/26715185.html

Form 144 GALECTIN THERAPEUTICS Filed by: Shlevin Harold H.

Mon, 29 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260629/26706525.html

Form 144 GALECTIN THERAPEUTICS Filed by: Shlevin Harold H.

Mon, 29 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260629/26706525.html

Form 144 GALECTIN THERAPEUTICS Filed by: Jamil Khurram

Fri, 26 Jun 2026 18:09:00 -0400

si-local-file:///var/storage/secattach/20260626/26700159.html

Form 144 GALECTIN THERAPEUTICS Filed by: Jamil Khurram

Fri, 26 Jun 2026 18:09:00 -0400

si-local-file:///var/storage/secattach/20260626/26700159.html

Form 144 GALECTIN THERAPEUTICS Filed by: Shlevin Harold H.

Fri, 26 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260626/26698886.html

Form 144 GALECTIN THERAPEUTICS Filed by: Shlevin Harold H.

Fri, 26 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260626/26698886.html

Form 4 GALECTIN THERAPEUTICS For: Jun 23 Filed by: Jamil Khurram

Thu, 25 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260625/26692330.html